In patients with NMIBC, FC-assisted TUR with 5-ALA results in a substantial recurrence and progression risk reduction as compared to WL-TUR. The single early postoperative instillation of doxorubicin did not have a statistically significant impact on recurrence and progression risks.
urinary bladder neoplasms ‹› chemotherapy ‹› adjuvant ‹› antineoplastic combined chemotherapy protocols ‹› cystectomy ‹› randomized controlled trial ‹› survival analysis Citation: Zhegalik AG, Polyakov SL, Rolevich AI, et al. Long-term results of a single-center prospective randomized trial assessing efficacy of a shortened course of adjuvant chemotherapy after radical cystectomy in patients with locally advanced bladder cancer. Cent European J Urol. 2020; 73: 26-32.in patients with pathologically locally advanced bladder cancer does not exceed 50% [3,4]. Neoadjuvant cisplatin-based combination chemotherapy is a standard strategy to improve treatment outcomes in patients with muscle-invasive bladder cancer undergoing RC with level 1 evidence of survival benefit [5]. However, adjuvant chemotherapy (AC) can be an alternative approach, the advantage of which is a more accurate selection of patients * including one febrile neutropenia case; ** the total exceeds 100% as several adverse events could be observed in one patient; AST -aspartate aminotransferase; ALT -alanine aminotransferase
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.